Back to results
US 11,453,881 B2Granted
Modified oligonucleotides for use in treatment of tauopathies
AssigneeJanssen Pharmaceutica NV
InventorsAndreas Ebneth, Constantin Van Outryve D'Ydewalle, Sergei Gryaznov, Saúl Martinez Montero, Leonid Beigelman, Vivek Kumar Rajwanshi
Life of this patent
Estimating the term…
Abstract
Oligonucleotides comprising modifications at the 2′ and/or 3′ positions(s) along with methods of making and use against Alzheimer disease and other tauopathies are disclosed.
Claims32
A chimeric oligonucleotide complementary to at least a portion of the MAPT gene represented by Formula (VI):
- 5′X-Y-Z3′ (VI),
- wherein
- X-Y-Z is a chimeric oligonucleotide comprising a sequence of 18 to 22 nucleosides, and is optionally conjugated at the 5′ and/or 3′ end to a ligand targeting group;
- X is a domain comprising a sequence of modified nucleosides that is 3-10 nucleosides in length;
- Z is a domain comprising a sequence of modified nucleosides that is 3-10 nucleosides in length;
- and
- Y is a domain comprising a sequence of 2 to 10 2′-deoxy-nucleosides linked through thiophosphate intersubunit linkages, and
- wherein the oligonucleotide shows affinity to at least one of SEQ ID NO:
- 3, SEQ ID NO:
- 4, SEQ ID NO:5 or SEQ ID NO:6,
- wherein the X and/or Z domain comprises one or more oligonucleotide where the modification is 2′-O-methoxyethoxy-N3′→P5′.
8 more elements
Dependencies are inferred from the claim text.